Cellebrite DI (NASDAQ:CLBT) CMO David Nicholas Gee Sells 4,323 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 4,323 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. The trade was a 3.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Nicholas Gee also recently made the following trade(s):

• On Friday, August 21st, David Nicholas Gee sold 2,198 shares of Cellebrite DI stock. The shares were sold at an average price of $11.24, for a total transaction of $24,705.52.
• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total transaction of $3,696.10.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $11.29 on Wednesday. The firm’s fifty day moving average price is $14.21 and its two-hundred day moving average price is $13.81. The stock has a market cap of $2.82 billion, a PE ratio of 51.32, a PEG ratio of 1.59 and a beta of 1.18. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. DA Davidson reduced their price target on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Weiss Ratings downgraded shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, August 13th. Lake Street Capital reduced their target price on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. cut their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive: five analysts maintain Buy ratings, and the consensus price target is $16.70. Lake Street, DA Davidson, JPMorgan and Needham all retained positive ratings despite lowering their targets. Analyst ratings and price targets
• Positive Sentiment: Institutional ownership remains substantial at approximately 45.9%, with several funds—including Principal Financial, Renaissance Technologies and Roubaix Capital—reporting increased positions. This may provide some underlying support for the stock. Institutional ownership data
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio. Because the figures imply no measurable short position and include an anomalous percentage change, they offer little useful signal for CLBT’s near-term direction.
• Negative Sentiment: Cellebrite’s chief marketing officer, David Nicholas Gee, sold an additional 4,323 shares worth about $49,100 on August 24, following a sale of 2,198 shares worth approximately $24,700 on August 21. The transactions reduced his holdings by 3.1% and 1.55%, respectively. The latest sale was conducted under a pre-arranged Rule 10b5-1 plan, which reduces—but does not eliminate—the bearish interpretation. CMO insider sale filing
• Negative Sentiment: The chief revenue officer, Marcus Jewell, sold 12,562 shares for approximately $141,200 on August 21. Multiple executive sales in a short period can pressure sentiment, particularly while the stock is well below its 52-week high. CRO insider sale filing
• Negative Sentiment: Kaplan Fox and Block & Leviton announced investigations into potential securities-law violations involving Cellebrite. The announcements do not establish wrongdoing, but they introduce legal and reputational risk and are likely contributing to selling pressure. Kaplan Fox investigation announcement

Hedge Funds Weigh In On Cellebrite DI

A number of hedge funds and other institutional investors have recently made changes to their positions in CLBT. Roubaix Capital LLC increased its holdings in Cellebrite DI by 108.1% in the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock worth $4,178,000 after purchasing an additional 157,536 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Cellebrite DI during the 1st quarter worth approximately $2,134,000. Principal Financial Group Inc. boosted its holdings in shares of Cellebrite DI by 33.9% during the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after buying an additional 545,334 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after buying an additional 365,700 shares during the period. Finally, Weiss Asset Management LP grew its position in shares of Cellebrite DI by 3,485.3% during the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after buying an additional 1,846,851 shares during the period. 45.88% of the stock is owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.